Hemagglutinin (HA) Informations sur la molécule
Molecule Name
Influenza virus hemagglutinin glycoproteins
Alias de la molécule
HA,Hemagglutinin
Drug Development Progress
Nombre de médicaments cliniques3
Nombre de médicaments commercialisés0
Phase de R&D la plus avancéePhase 1 Clinical
Alias de la cible
Hemagglutinin，HA，Hemagglutinin Glycoproteins， Influenza Virus
Hemagglutinin (HA) Liste de produits
Species
- Influenza (A/Wisconsin/67/2022)（1）
| Cat. No. | Product Name | Size&Price | Add to Cart |
|---|---|---|---|
Mouse Anti-Influenza (A/Wisconsin/67/2022) Antibody IgG Titer ELISA Assay Kit (HA) | $670.00 96tests |   |
You Have Viewed 1-1 Of 1 Results
FAQ
How should the HA titer kit be stored?
Store the unopened kit at 2–8°C. After opening, the stated shelf life is 30 days, with component-specific storage requirements.
How should a vaccine study use this endpoint?
Treat the result as an HA-specific IgG-titer readout; it does not alone measure neutralizing activity.
What ELISA format does the HA titer kit use?
It uses indirect ELISA. Follow the kit instructions for plate setup, sample dilution, and titer calculation.
Which species and strain are specified?
The product is specific to mouse serum and influenza A/Wisconsin/67/2022; do not assume cross-strain compatibility.
Does this kit measure HA antigen concentration?
No. The listed kit measures mouse anti-HA IgG titer, rather than the concentration of HA protein.
What research use is stated for the kit?
It is presented for evaluating immunogenicity during preclinical influenza vaccine development.
What sample type does RAS-T226 use?
The kit is designed for mouse serum. Follow its dilution and handling instructions.
Which kit supports HA-specific IgG measurement in mouse studies?
RAS-T226 measures mouse IgG against influenza A/Wisconsin/67/2022 hemagglutinin (HA).
Asset Licensing Opportunity
Resources
Informations sur les médicaments cliniques
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| Anti-influenza monoclonal antibody (AIMM Therapeutics) | Phase 1 Clinical | Aimm Therapeutics | Influenza, Human | Details | |
| cH8/1N1 LAIV | Phase 1 Clinical | Icahn School Of Medicine At Mount Sinai | Influenza, Human | Details | |
| Ad4-H5-Vtn (Emergent BioSolutions/National Institute of Allergy and Infectious Diseases) | Phase 1 Clinical | Emergent Biosolutions Inc | Communicable Diseases | Details |
Customer Reviews